A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
PHASE2CompletedINTERVENTIONAL
Enrollment
3
Participants
Timeline
Start Date
June 1, 2022
Primary Completion Date
July 2, 2022
Study Completion Date
July 2, 2022
Conditions
Cryopyrin Associated Periodic Syndrome
Interventions
DRUG
ZYIL1 capsule
NLRP3 inflammasome inhibitor
Trial Locations (1)
5000
Department of Clinical Immunology and Allergy, Adelaide